Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients
about
ALK: a tyrosine kinase target for cancer therapy.Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.ALK alterations and inhibition in lung cancer.The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer.The combination of checkpoint immunotherapy and targeted therapy in cancer.EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).PD-L1 expression in inflammatory myofibroblastic tumors.STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis.Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer.Oncogene-addicted non-small cell lung cancer and immunotherapy.First-line alectinib for ALK-positive lung cancer: is there room for further improvement?Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung CancerCons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?Autochthonous murine models for the study of smoker and never-smoker associated lung cancers
P2860
Q37518624-5173550E-D71D-4BFB-8E61-D6BCA90B3502Q38720801-9A115A41-1B0D-4438-962D-18FE30A531D6Q38740295-A29F1BB9-FF3E-44E2-9DE7-563FD366DB47Q38820412-1C41D658-EBE9-40D4-9D20-2A707209972FQ38998427-094F74AD-1ED1-468E-94AE-52FF6CB736BDQ39027385-1439AEB4-EFD3-4C09-9581-089FE05E7F7CQ40223999-3D5E8BC4-422C-4CED-9F82-A73CE1A253DBQ41306256-04353CDB-850B-4D0A-A661-FC2DED5F9F9AQ41912025-CDD9AD95-29F6-48FF-B9C8-C4412F03B859Q42644265-48C872FC-3AB4-4F47-AA7A-0D1A5A566CAEQ46793262-46281166-837E-48A3-8A98-B3224F142E19Q47100314-6BF6A160-E557-41F4-B56F-2F6678785A50Q47214499-B7C286A7-3B84-40FA-BAE7-2E500C36F1E6Q49188022-EB9898A0-E8A9-485B-A41A-B18F3D62774DQ49957848-61459A95-753D-4B21-9740-DC5CF78023CCQ52317592-73790598-1828-4DC7-A0C6-52BBA336A820Q52684139-888266E9-F2D7-4D81-9711-41A8D7732125Q55194789-2E939205-4A2D-4C77-9597-95C8FF97716DQ55445279-FB722A58-907C-46BD-9234-9D67AA7B54E5Q55712374-B4D0CD37-5DA1-4A92-B9A6-0CFE4BD91BD0Q57174372-921042F0-8D35-46C5-9516-AF37F472B6B7Q58562294-C19CE2B0-D442-4FB9-8F7C-ACB4C6B2A1ABQ58804389-0CAD8447-427E-40B1-8CAE-2B0DEB5AB0A6
P2860
Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Upregulation of PD-L1 by EML4- ...... e and resistant NSCLC patients
@en
type
label
Upregulation of PD-L1 by EML4- ...... e and resistant NSCLC patients
@en
prefLabel
Upregulation of PD-L1 by EML4- ...... e and resistant NSCLC patients
@en
P2093
P2860
P1433
P1476
Upregulation of PD-L1 by EML4- ...... e and resistant NSCLC patients
@en
P2093
Jianhua Zhan
Jiaxing Huang
Shaodong Hong
Shiyang Kang
P2860
P304
P356
10.1080/2162402X.2015.1094598
P577
2015-12-21T00:00:00Z